The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...

Please provide your email address to receive an email when new articles are posted on . A review found that OCT and visual acuity were among the most popular benchmarks in the management of diabetic ...

Intraretinal hyperreflective foci, intraretinal hard exudates, and epiretinal membrane formation were lower after treatment with faricimab (Vabysmo) compared with aflibercept (Eylea) for patients with ...

Resistant diabetic macular edema may necessitate transitioning from one intravitreal pharmacotherapy to another when the edema is persistent — a practice sometimes undertaken in clinical management.

A newly published study found that intravitreal injection of autologous CD34+ stem cells is well tolerated and feasible for treating loss of vision resulting from central retinal vein occlusion (CRVO) ...

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of ...

ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today ...

Daily habits can make a meaningful difference when you have diabetic macular edema (DME). Learn how blood sugar control, healthy blood pressure, nutrition, exercise, and consistent eye care can help.

Patients with diabetic macular edema can expect similar BCVA improvements and CST reductions using an aflibercept biosimilar compared with conventional aflibercept. An aflibercept biosimilar is ...

Some patients with nonproliferative diabetic retinopathy had reduced vascular leakage or macular exudation after being treated orally with danegaptide, according to a study presented at Angiogenesis, ...